Market Intelligence, Clinical Progress, and High-Purity Reagents for Cystic Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CFTR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Lentivirus) | CFTR Lentivirus (Wild-Type & F508del); High titer, optimized for complex ion channel expression in stable cell lines. | View CFTR Products |
| Antigen (Recombinant Domain) | CFTR Recombinant Domain Proteins (NBD1 WT, NBD1-F508del, NBD2); >95% purity, <1EU/ug endotoxin, HEK293 expressed. | View CFTR Products |
| Gene Delivery | CFTR Promise-ORF / Lentivirus Premade Particles; Full-length ORF, Sequence Verified, for stable cell line construction. | View CFTR Products |
| Benchmark Ab | Anti-CFTR Control Antibody / Reference Antibody; Recombinant positive control for Western, Flow Cytometry, and IHC. | View CFTR Products |
| Validator | CFTR siRNA Set; For specific knockdown verification in cell-based assays. | View CFTR Products |
| Related Target A | SCNN1A (ENaC); Epithelial sodium channel, frequently hyperactive in CF, synergistic target. | View SCNN1A Products |
| Related Target B | SLC26A9; Alternative chloride channel, bypasses CFTR dysfunction. | View SLC26A9 Products |
| Related Target C | ANO1 (TMEM16A); Calcium-activated chloride channel for CFTR bypass strategies. | View ANO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Membrane Folding | Lentivirus Premade Particles optimized for native membrane insertion and patch-clamp assays. |
| Mutation-Specific Screening (F508del, G551D, N1303K) | Sequence Verified mutant ORF clones and recombinant domain proteins (NBD1 WT/F508del, NBD2) available. |
| Lack of Reliable Controls | Benchmark recombinant antibodies and clinical reference modulators included. |
| Target Specificity Validation | Validated siRNA included for background signal elimination and false positive checks. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog CFTR domain proteins with >95% purity, endotoxin <1EU/ug. |
Live CFTR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CFTR therapeutics is intensifying, with major players shifting focus from traditional small molecule correctors and potentiators to genetic medicines and next-generation modalities. First-generation triple-combination therapy (elexacaftor/tezacaftor/ivacaftor) by Vertex Pharmaceuticals now covers approximately 90% of CF patients with at least one F508del mutation. However, the next wave of R&D is targeting nonsense mutations (e.g., W1282X), rare variants, and durable airway restoration via AAV, lentiviral, and mRNA platforms. Companies like Sionna Therapeutics and AbbVie are developing novel correctors with alternative binding sites, while genetic medicine players (Translate Bio, ReCode, 4D Molecular Therapeutics) aim for permanent functional restoration. Alternative chloride channels (SLC26A9, ANO1) and ENaC inhibitors are also being explored as synergistic or bypass strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules (Modulators) | Vertex, Sionna, AbbVie, Flatley Discovery Lab | Cystic Fibrosis (F508del, G551D, rare variants) | Trafficking & binding assays (Need mutant lentivirus cell lines, high-purity NBD1/MSD domain proteins) |
| Gene Therapy (AAV / Lentiviral) | Translate Bio, ReCode, 4D Molecular Therapeutics, Spirovant | CF (nonsense mutations, null mutations) | Expression validation (Need full-length ORF lentivirus, benchmark antibodies) |
| mRNA / CRISPR | Arcturus Therapeutics, Intellia Therapeutics | CF (rare variants) | Delivery & restoration validation (Need CFTR ORF lentivirus as positive control) |
| Alternative Channels | Enterprise Therapeutics | CF (all genotypes) | Selectivity screening (Need ENaC/SLC26A9/ANO1 specific controls) |